News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
Health & Biotech
Here’s how Immutep and other immunotherapy biotechs have changed cancer treatment
Health & Biotech
Check Up: Here’s what’s in store for the Healthcare sector as the new government steps in
Health & Biotech
ASX Health Stocks: Imugene begins Phase 1 trial of its cancer-fighting virus
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: Ecstasy for Emyria in MDMA trial, Beamtree wins US$7m deal
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
News
ASX Large Caps: ASX 200 trips over again, Brainchip gains another 15pc for no reason
Health & Biotech
ScoPo’s Powerplays: Health stocks tumble but half-price sale presents buying opportunities
News
ASX Large Caps: Nowhere to hide as Tech, Real Estate get smashed ahead of RBA call
News
Closing Bell: Sinking local markets jump ship as Central Bank prepares to board
Health & Biotech
Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death
News
ASX Large Caps: Blue chips fight back as oil prices climb back to US$105
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
Health & Biotech
ASX Health Stocks: 2 immunotherapy biotechs announce progress on clinical trials
Health & Biotech
ASX Health Stocks: Neuren, Imugene and RadioPharm have sights on new clinical trials
Health & Biotech
ASX Health Stocks: Clinuvel reveals study results, and Cann’s Mildura cannabis facility is a go
News